Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase 3
Active, not recruiting
- Conditions
- Recurrent NeuroblastomaRegional NeuroblastomaStage 4S NeuroblastomaStage 4 NeuroblastomaLocalized Resectable NeuroblastomaLocalized Unresectable Neuroblastoma
- Interventions
- Drug: IsotretinoinBiological: AldesleukinOther: Laboratory Biomarker AnalysisBiological: DinutuximabOther: Pharmacological StudyOther: Quality-of-Life AssessmentBiological: Sargramostim
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1449
- Registration Number
- NCT00026312
- Locations
- 🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸UCSF Medical Center-Mission Bay, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath